Clinical TrialMay 27, 2026, 07:02 AM
Sagimet's denifanstat/resmetirom Phase 1 data named Best of EASL 2026
AI Summary
Sagimet Biosciences announced that its Phase 1 clinical data for the denifanstat/resmetirom combination therapy was selected as a "Best of EASL 2026" presentation. The trial in healthy adults demonstrated the combination was generally well-tolerated and led to rapid, significant reductions in total and LDL cholesterol levels after two weeks, suggesting a potential cardiovascular benefit. Preclinical data also supported the synergistic effect of the combination in improving liver histology and lipid lowering in MASH models.
Key Highlights
- Sagimet's denifanstat/resmetirom Phase 1 data selected as "Best of EASL 2026".
- Phase 1 trial showed combination was generally well-tolerated with no safety signals.
- Cohort 1: total cholesterol reduced by 23mg/dl, LDL cholesterol by 17mg/dl.
- Cohort 2: total cholesterol reduced by 16mg/dl, LDL cholesterol by 14mg/dl.
- Rapid reductions in cholesterol levels (p<0.001) observed after two weeks.
- Preclinical data showed improved liver histology and lipid lowering in MASH models.
- Results support potential for MASH and liver fibrosis treatment.
Price Impact
More from SGMT